Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases

20-40% of patients with NSCLC will develop brain metastases at some point during their course of the disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with leptomeningeal disease in the phase 1 BLOOM study. Stereotactic radiosurgery (SRS) is one of the standard local treatment for patients with limited number of brain metastases. Currently, it is unclear whether adding SRS to Osimertinib will result in superior intracranial disease control in patients with EGFR mutated NSCLC with brain metastases diagnosed de novo or developed while on first line EGFR tyrosine kinase inhibitors (TKIs) such as Erlotinib and Gefinitib. The aim of this study is to compare the effects of Osimertinib alone versus Osimertinib plus SRS on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Participating Centres

Accrual Target

80

Current Accrual

Expected Date of Accrual

August 2022

Trial Chairperson

A/Prof Chee Lee, St George Hospital, NSW, Australia
Dr Fiona Hegi-Johnson, Peter MacCallum Cancer Centre, VIC, Australia
Dr Yu Yang Soon, National University Hospital Singapore
Dr Ivan Tham, National University Hospital Singapore
Dr Ross Soo, National University Hospital Singapore

Clinical Trial Registration

Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a